We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Absology

ABSOLOGY is a medical equipment manufacturer that develops and mass-produces in vitro diagnostic medical devices. ABS... read more Featured Products: More products

Download Mobile App





Absology Exhibits POCT Immunoassay Analyzer with Testing Time of Five Minutes

By LabMedica International staff writers
Posted on 16 Nov 2022

Absology Co. More...

, Ltd. (Gyeonggi-do, Korea) is participating in MEDICA 2022 where the company is exhibiting its POC FIA (Fluorescence Immunoassay) analyzer that uses microfluidic technology for the accurate quantitative diagnosis of concentration of biomarkers for a range of diseases.

At MEDICA 2022, Absology is showcasing its ABSOL POCT analyzer that uses FIA technology to quantitatively diagnose the concentration of biomarkers. It has a test time of only five minutes and features a vivid expressed GUI along with a convenient built-in printer. Alongside ABSOL, the company is showcasing the ABSOL HS high-sensitive ELISA analyzer for early disease screening. ABSOL HS can detect Femtogram level molecules using Absology’s proprietary PIFA (Photooxidation Induced Fluorescence Amplification) technology. It has a test time of only 30 minutes and requires just 20uL of blood sample. Compact and affordable, the portable and light weight ABSOL HS is a flexible platform for any kind of ELISA protocol. Absology offers a wide test menu for the ABSOL and ABSOL HS systems, including PSA, Testosterone, Vitamin D, TSH, FreeT4, Thyroid Combo, Cortisol, PCT, COVID-19 IgM/IgG, COVID-19 Ag, COVID-19 Neutralizing Antibody, and Influenza A/B.

Related Links:
Absology Co., Ltd. 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Acute lymphoblastic leukemia in children and young people requires careful relapse risk assessment as treatment expands beyond standard chemotherapy. (Image Credit: Shutterstock)

New Risk-Stratification Tool Predicts Relapse After Blinatumomab in Childhood ALL

Acute lymphoblastic leukemia in children and young people requires careful assessment of relapse risk, particularly as treatment approaches move beyond standard chemotherapy. Traditional relapse predictors... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Decentralized Laboratory Network Improves Detection of Viral Hemorrhagic Fevers in Guinea

Viral hemorrhagic fevers remain a major diagnostic challenge in West Africa because their early symptoms can resemble those of other febrile illnesses. The 2014–2016 Ebola epidemic underscored the need... Read more

Pathology

view channel
Image Credit: Adobe Stock

AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification

In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.